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Background: Chronic subdural hematoma (cSDH) is a common neurosurgical disease. It is often considered to be a
rather benign entity. In spite of well established surgical procedures cSDH is complicated by a recurrence rate up to
30%. Since glucocorticoids have been used for treatment of cSDH in 1962 their role is still discussed controversially
in lack of evident data. On the basis of the ascertained inflammation cycle in cSDH dexamethasone will be an ideal
substance for a short lasting, concomitant treatment protocol.
Objective: to test the efficacy of dexamethasone on reduction inthe reoperation rate of cSDH.
Methods/Design: The study is designed as a double-blind randomized placebo-controlled trial 820 patients who
are operated for cSDH and from the age of 25 years are included after obtaining informed consent. They are
randomized for administration of dexamethasone (16-16-12-12-8-4 mg/d) or placebo (maltodextrin) during the first
48 hours after surgery. The type I error is 5% and the type II error is 20%. The primary endpoint is the reoperation
within 12 weeks postoperative.
Discussion: This study tests whether dexamethasone administered over 6 days is a safe and potent agent in
relapse prevention for evacuated cSDH.
Trial registration: EudraCT 201100354442
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Chronic subdural hematoma (cSDH) is a common
neurosurgical disease: Its one-year incidence rate is
about 5 per 100,000 in the general population, but in-
creases for those aged 70 years and older (58 per
100,000 per year) [1]. Because the proportion of people
aged 65 years and older is expected to double worldwide
between 2000 and 2030 [2], a large rise in incidence is
expected.
Despite its relatively high mortality and morbidity it is
often considered to be a rather benign entity [3,4]. The* Correspondence: s.emich@salk.at
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reproduction in any medium, provided the ormain risk defining the outcome is recurrence. Even if
operated by skillful neurosurgeons, recurrence rates
from 3.8 to 30% are reported [4-6].
cSDH was first described by JJ Wepfer [7] in 1656,
followed by Rudolf Virchow, [8] who detected an inflam-
matory element and in 1856 named this condition
pachymeningitis haemorrhagica interna. The formation
of new membranes and the extravasation of fluid in the
cavity between these membranes and layers was seen by
Virchow as typical for this disease. Today’s definition
of chronic subdural hematoma as a 'chronic, self-
perpetuating inflammatory process that involves the
dura mater' was given by Frati [9] and confirms the in-
flammatory nature of this disease.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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origin. Analogous to acute subdural hematoma caused
by trauma, the occurrence of chronic subdural hematoma
has often been described in conjunction with head injury.
Histopathological evidence for the influence of trauma
was given by Schachenmayr [10] in 1978 describing that
after microtrauma a cleavage of the inner dural layer
occurs ('tissue torn artifact'). Still today the role of head
trauma in the origin of chronic subdural hematoma is not
clear. A literature search discloses that at least mild head
trauma had occurred in 8% [11] to 80% [12] of the
patients.
An important histopathological mechanism of origin is
the high non-specific reaction potential of the capillary
network in the inner dural sheet which, coming in con-
tact with blood or fibrin degredation products, leads to
the formation of a neomembrane. This mechanism is
supported by the inflow of liquids like blood, later
plasma and/or cerebrospinal fluid (CSF. Further progres-
sion is maintained by tissue activator (TA) exuding from
the extremely vascularized membranes into the cavity,
perpetuating a fibrin/fibrinogene mechanism leading to
continuous microhemorrhages. Furthermore the auto-
membrane developes inflammatory cells, like mastcells,
eosinophiles, neutrophiles, monocyts, macrophages, endo-
thelial cells and fibroblasts, being continuously activated
and recruited. This constitutes a source of inflammatory
angiogenic fibrinolytic and coagulation factors [9].
The symptomatology consists of headache, neurological
focal symptoms, aphasia, epilepsy and unconsciousness.
After assessment of the symptoms a neurological classifi-
cation can be made grading the patients from grade
0 to grade 4 [12]. The main diagnosis however, is
done by imaging. Computerized tomography (CT) and
magnetic resonance imaging (MRI) disclose monolateral
or bilateral extracerebral fluid with more or less
membranes separating the hematoma into chambers.
Different classifications for both imaging tools are
available [13-15].
The primary therapeutic option is surgery. The stand-
ard procedure consists of a burr hole above the site of
the lesion with or without irrigation. Santarius [16] has
proved that an insertion of a drain diminishes recur-
rence and mortality at 6 months after burr hole craniost-
omy. In cases of separation of the hematoma by thick
layers, open craniotomy must be chosen to allow for
evacuation of all chambers [17]. Recurrence of the
hematoma is defined as reappearance of the clinical and
radiological symptoms and leads to reoperation.
The first remark about a nonsurgical treatment of
cSDH was given by Ambrosetto [18] in 1962. He de-
scribed four patients, who received a conservative multi-
modal therapy in combination with corticosteroids:
Their clinical symptoms regressed completely. Frati [9]and Labadie [19,20] reported that due to the proof of
proinflammatory and inflammatory cytogene that anti-
inflammatory therapy may be beneficial. However, several
national surveys show a controversial use of cortisone in
treatment of cSDH: 38% of French neurosurgeons use ad-
juvant corticosteroid therapy after surgery [21]. For 13% of
Canadian neurosurgeons cortisone plays a role in the
treatment of cSDH [22], and 55% of surgeons in the UK
and Ireland prescribe steroids in conservatively managed
patients [23]. Berghauser Pont [24] wrote about a gener-
ous use of corticosteroids in a nonsurgical setting and in
preparation for surgery respectively, in combination with
surgical treatment in the Netherlands.
There are only poor data published about the efficacy
of concomitant cortisone medication. Sun [25] describes
112 cases treated in a prospective set-up. A systematic
review regarding corticosteroids and cSDH [26] found
that beyond Sun’s trial there are only four retrospective
studies and concludes that steroids are beneficial and
suggests more prospective data are needed. Berghauser
Pont also performed a retrospective cohort study [27] of
patients with cSDH on preoperative corticosteroid ther-
apy. If there were no signs of recovery patients under-
went surgery: 496 patients with burr hole craniostomy
were enrolled. Recurrence was stated at 11.9. In spite of
preselection the basis of cortisone therapy, the relapse
rate is low.
In 2011 Park published a prospective study about
cSDH [28]: 31 patients underwent burr hole irrigation
plus external drainage. The objective of this study was to
investigate the relationship between fibrinolytic factors
and computed tomography findings. We emphasize in
this trial the postoperative administration of dexametha-
sone for one week, because the reoperation rate Park de-
scribed was only 3.2.
Thus, the DRESH study will be the first randomized
controlled trial (RCT) to evaluate the role of a short
postoperative cortisone protocol in the operative treat-
ment of cSDH.
Choice of comparator
Dexamethasone has been selected because contrary to
methylprednisolone, it is independent of weight, allow-
ing for a simplified randomization and blinding proced-
ure. Other advantages of dexamethasone are the longest
biological half-life of all glucocorticoids (36 to 54 hours)
and seven times higher potency than prednisolone. The
total dosage used in the DRESH study is 68 mg in
Austria and 68.25 mg in China, which is equivalent to a
two times higher dosage of prednisolone (1 mg/kg/day).
The drug concentration in CSF correlates with the peak
concentration in plasma. The DRESH study considers
these pharmacokinetics by a single dose at a physio-
logical time in the morning.
Table 1 List of Chinese study cites
Address of hospital ZIP code
1 Jiangsu Province Xuzhou Hospital 221009
2 Neimeng Medical University 1st Affiliated Hospital 22150
3 Shanxi Province Datong 5th Hospital 37006
4 Gansu Province Wuwei Hospital 733000
5 Neimeng Province Linye Hospital 22150
6 Shanxi Province Liangzhou Hospital 726000
7 Guangdong Province Baoan Central Hospital 518101
8 Hebei Province Tangshan Central Hospital 63300
9 Heibei Province Tang Country 1st Hospital 262400
10 Qing Hai Province People Hospital 810007
11 Guizhou Province Zunyi Central Hospital 441000
12 Henan Province Anyang Local Hospital 455000
13 Guangxi Province 1st Hospital 455000
14 Guangdong Province Huizhou 1st Hospital 530021
15 Shandong Province Qingdao 1st Hospital 516000
16 Shandong Province Longkou Central Hospital 266400
17 Shandong Province Cangshan People’s Hospital 265701
18 PLA 2nd Hospital 100037
19 Harbin Medical University 4th Affiliated Hospital 431700
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Primary objective
The primary objective is to demonstrate that dexametha-
sone reduces the reoperation rate by 50% within 12
weeks after hematoma evacuation.
Secondary objectives
The secondary objectives of the study are as follows: to
measure the effect of dexamethasone on clinical out-
come by the Markwalder score during a period of 12
weeks after surgery; the impact on radiologic signs of
the hematoma, such as thickness, membranes and mass-
demanding effect (midline-shift); to evaluate risk factors
of the genesis and recurrence of cSDH in a prospective
study design; risk of infectious complications, for ex-
ample, pneumonia, urinary tract infection, ventriculitis,
meningitis and encephalitis; dexamethasone-dependent
severe psychiatric reactions; and death.
Trial design
This is a phase III, prospective, multi-center, double
blind, randomized, placebo-controlled study. Eligible
participants are randomized in a 1:1 allocation ratio to
one of the two arms: an intervention arm, in which the
participants receive dexamethasone according to the
protocol, and a control arm in which they receive
placebo.
Methods
Study setting and participants
Patients will be recruited from 19 Departments of
Neurosurgery in China that are in close contact to the
Capital Medical University Beijing (Table 1) and from
the Department of Neurosurgery, Paracelsus Medical
University Salzburg, Austria. The study is the first com-
mon project of cooperation between both medical
universities.
Inclusion criteria
The inclusion criteria are: 1) patients who are to
undergo surgery for cSDH according to one or both
of the following criteria: clinical symptomatology
(Markwalder grade 1 to 4) with correlation to the
cerebral lesion, or radiologic finding of cSDH with
flattening of the underlying cortex and/or midline
shift more than 5 mm; and 2) male or female patients
aged over 25 years (inclusive).
Exclusion criteria
The exclusion criteria are: 1) pregnancy and nursing; 2)
diabetes; 3) hypertension (systolic blood pressure (SBP)
>180 mmHg) that is refractory to treatment; 4) glau-
coma; 5) Known hypersensitivity to dexamethasone; 6)
known peptic ulceration; 7) acute systemic infection(fever, leucocytosis, elevated C-reactive protein (CRP)
and/or PCT (Procalcitonin); 8) parasitic infection; 9)
current or previous history of severe affective disorders
(especially previous steroid psychosis); 10) recent myo-
cardial infarction (as myocardial rupture has been re-
ported); 11) patients for whom study drug cannot be
started within 48 hours after evacuation of the hematoma;
12) patients for whom it is known at the time of screening
that certain follow-up, protocol-mandated imaging assess-
ments will not be feasible; 13) patients unlikely to comply
with the protocol (for example, unable to return for
follow-up visits); 14) current alcohol or drug abuse, or de-
pendence; 15) use of another investigational product
within 28 days prior to randomization; 16) vitamin-K an-
tagonists during the first 2 weeks after operation; 17)
GpIIb/IIIa-receptor antagonists, ASS (acetylsalicylic acid)
or NOAC (new oral anticoagulants) during the first two
weeks after surgery; and 18)
reoperation within 48 hours after the first operation.
Interventions
Investigational drug
The intervention which will be evaluated in this trial is
the intake of dexamethasone. In Austria the tablets are
provided in capsules of 4 mg each and are taken orally
before 8.00 in the morning. The daily dosages are 16 mg
at days 1 and 2, 12 mg at days 3 and 4, 8 mg at day 5,
and 4 mg at day 6. In China there are only tablets of
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with six, four or three tablets. The following dosages can
be obtained: 15.75 mg at days 1 and 2; 12 mg at days 3
and 4; 8.25 mg at day 5 and 4.5 mg at day 6. This inter-
vention will be compared against placebo.
Comparative drug
Matching oral capsules are filled with maltodextrin to
the same weight and are administered similarly.
Concomitant care
All patients in the study will receive the routine standard
of care. This will include a check of blood and vital pa-
rameters, a neurologic investigation and CT scan at ad-
mission. An acute onset of neurologic deterioration or a
decline of alertness will need an urgent operative treat-
ment. For neurosurgical procedures normal coagulation
parameters are essential. In warfarin medication, the
international normalized ratio (INR) has to be normal
prior to surgery. Coagulation factors or other blood
products will be administered as required. ASS is to be
stopped five days and GpIIb/IIIa-receptor antagonists
seven days before surgery, and NOAC a duration longer
than double of their pharmacological half-life. Only
those patients are eligible who are able either to pause
their anticoagulant or antiplatelet medication, or to tol-
erate a conversion to LMWH (low molecular weight
heparin) for two weeks postoperatively.
In consideration of different techniques available for the
evacuation of a chronic subdural hematoma, the following
procedure has been agreed: one burr hole over the site of
the hematoma, no irrigation and a closed drainage system.
The drain will be continued up to 48 hours. Criteria for
discontinuing before 48 hours are air in the system, an in-
corrigible flow arrest or delivery of pure CSF.
Pain will be treated according to the WHO guidelines
[29].
LWMH are used for deep venous thrombosis prophy-
laxis. The application has to start within 24 hours post-
operatively, or if the patient is mobile, less than 3 hours
a day. Daily neurologic investigations and control of vital
parameters and wound healing will be added to standard
care, as will concerted medication and drawing of blood
samples, CT scans and physical therapy as necessary.
There will be a focus on hyponatremia and pathologic
INR values. Patients who received oral anticoagulation
preoperatively will need to be controlled daily and will
have to have their parameters kept within the normal
range throughout the hospital stay. The same procedure
will be applied in hyponatremia. At study day-3 blood
glucose levels are evaluated. At a level higher than
300 mg/dl the patient will be excluded from the trial. In
order to detect a raised intraocular pressure a measure-
ment will be performed during the treatment period.Participants will remain inpatients until the study drug
is administered completely. Patients who ready to be dis-
charged home earlier will have to finish the medication on
their own. Protocol-mandated assessments will be per-
formed according to the table of assessments (Table 2).
CT and/or MRI scans will be sent to a core laboratory and
evaluated centrally in a triple-blinded way. Blood samples
will be analyzed by the investigational laboratory locally.
Two regular follow-up visits are planned. At weeks 4
and 12 after the operation a CT scan and clinical investi-
gation are performed. Only in the case of reoperation is
another visit necessary as an outpatient at week 24.
Concomitant medications will be proton pump inhibi-
tors, vitamin K and anticonvulsants as required. In
addition participants will have to avoid traditional medi-
cines (that is, plant-, animal- or mineral-based medicine,
such as traditional Chinese medicine).
Outcomes
Primary Outcome Measures
It is considered that the prevention of reoperation would
be the most important clinically primary endpoint.
Secondary Outcome Measures
Secondary outcomes include clinical evaluation by the
Markwalder score and radiologic characteristics of the
CT/MR images over time. On axial CT scans the thick-
ness of the hematoma and midline shift is measured in
millimeters at the thickest area and the volume is calcu-
lated in cubic centimeters. Midline shift is measured at
the level of the intraventricular foramen. Hematomas
are classified as homogenous, laminar, separated or tra-
becular. Their location is classified as being over the
convexity, at the cranial base or the interhemispheric
space. There is also a focus on brain atrophy that is clas-
sified as none, mild, definite, or severe. Residual air is
measured in cubic centimeters. The influence of a pa-
tient’s long-term medication is evaluated together with
coexisting diseases as predictors for recurrence.
Participant timeline
A time schedule of enrolment, interventions, assess-
ments and visits for participiants are shown in Table 2.
The flow diagram (Figure 1) illustrates the key steps of
the trial.
Sample size
Let pverum be the reoperation rate in the verum group
and pplacebo be the reoperation rate in the placebo group.
The null hypothesis H0 is that the ratio of both rates
pplacebo /pverum is equal or smaller than 2, the corre-
sponding alternative hypothesis H1 is that the ratio
pplacebo /pverum is larger than 2. In other words, the alter-
native hypothesis states that dexamethasone reduces the

















Procedure related information x
Randomization x
Concomitant medications2 x x x x x x




Urine pregnancy test x
Markwalder score x x (OD) x x x
Blood glucose x
Intraocular pressure x
Neurological worsening events x x x
CT scan x5 x6 x x x
Post-discharge information x x7 x
Adverse events x x x8
Serious adverse events x9 x9 x x x x x10
OD=once a day.
CT=computer tomography.
1Only in case of reoperation.
2Concomitant medications will be recorded in the CRF from 2 weeks prior to study drug start and up to the end of study drug medication.
3Blood will be analyzed locally and the results will be recorded in the CRF.
4Preoperative oral anticoagulated patients need a coagulation monitoring once a day to keep the parameters normal. In the same way are patients monitored
with hyponatremia.
5If the baseline CT scan performed at a referral center, is of acceptable quality, and is available at the investigational site at the time of screening, it does not
need to be repeated. However, if the only baseline CT scan available is a hardcopy film, then it must be repeated at the investigational site.
6CT scan to be performed during 48h post operation. In case of neurological worsening CT scans are repeated as required.
7At week 12 the patient will return to the hospital for documentation of his/her residence (e.g. home, rehabilitation centre etc.), any new hospitalizations or
surgical procedures (directly or indirectly related to the cSDH) since the first hospital discharge, and to ensure that ongoing AEs/SAEs or new SAEs are followed
up/documented. In case of reoperation the same procedure is performed at week 24.
8AEs reporting and follow-up: Reporting of all new AEs up to one day after study drug discontinuation; follow-up of ongoing AEs only thereafter.
9SAEs related to study-mandated procedures after signature of informed consent and before study drug administration.
10Serious adverse events still ongoing at the Study Completion visit must be followed until resolution or stabilization or until the event is otherwise explained.
New SAEs occurring at any time after the 21-day follow-up period after study drug discontinuation may be reported to the Sponsor within 24 hours of the investi-
gator´s knowledge of the event, if felt appropriate by the investigators.
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cation the effect size is assumed to be this size because
dexamethasone will be taken by the majority without
benefit.
The assumed reoperation rate pplacebo is 10%. This is
in accordance with the data from our department and
the Chinese study sites. In order to detect a ratio pplacebo /
pverum of 2 or more with a power of 80%, the sample
sizes are n1 = n2 = 370 in each arm. The type I error is
5% and the type II error for this scenario is 20%. The
actual power of 83% is based on the exact power for the
ratio of two binomial populations, one-sided and based
on the score test (StatXact Cytel Software Corporation
(2002) StatXact 6.0 For Windows User Manual, Cytel
Software Corporation, Cambridge MA, USA). Due to
possible drop-out of patients, we increased the sample
sizes up to 410 in each group. Thus, 820 patients under-
going surgery for cSDH will be included.Randomization
Stratified randomization is done by using a computer
randomization algorithm to generate balanced random
samples (PASS 11, Hintze, J (2012). NCSS 8, NCSS, LLC.
Kaysville, Utah, USA. www.ncss.com and Rosenberger, WF,
and Lachin, JM 2002. Randomization in Clinical Trials -
Theory and Practice. John Wiley & Sons. New York.)
within each study site. Study site is the stratification vari-
able for this randomization plan. Hence, the number of pa-
tients who receive verum medication is the same as the
number of patients who receive a placebo in each study
site, a 1:1 allocation ratio. Each patient receives a unique
integer number ranging from 1 to 820 as an identification
code, and this number will also be assigned to the corre-
sponding medication kit. Each study site has a predefined
set of patients to complete. In order to avoid consecutive
recall of medication kits, the sequence in each study site is













Operation - day 0 
Randomization
Performed at any time after admission
study drug application has to start within 48 hours 
postoperatively
Treatment period
Day 1 to 6 of study drug medication
Markwalder score daily
Blood glucose and intraocular pressure on Day 3
Neurological worsening events
Adverse and serious adverse events
Follow-up period
Week 4 and 12 post surgery




Adverse and serious adverse events 
Figure 1 Flow diagram.
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interactive web response system (IWRS) and hence the
randomization is available for each study site. The investi-
gators (or study staff ) will interact with the system to re-
ceive the information as to which study group the patient
is allocated, and which medication kit has to be used.Data analysis
The primary endpoint is the rate of reoperation between
48 hours and 12 weeks after the initial evacuation of a
chronic subdural hematoma. Mandatory reoperation dur-
ing the first 48 hours is related to surgical com-
plications. In such rare cases the patient will be excluded.
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computing crosstabulation tables and applying Pearson’s
chi-square test. Data will be checked carefully for out-
liers and for normality based on the Kolmogrov-Smirnov
test and Liliefors test. To evaluate the impact of dexa-
methasone on the thickness of the hematoma and other
continuously distributed, metrically scaled variables,
mixed models with treatment group as the independent
factor and time as the repeated factor will be applied (if
all assumptions for the model are met). Linearity will be
assessed by Box Tidwell and log transformation. Corre-
sponding planned contrasts together with 95% confi-
dence intervals will be computed. If these variables
do not fulfill the assumptions for parametric testing,
nonparametric methods such as the bootstrap t-test,
Kruskal-Wallis analysis of variance (ANOVA) with
median tests and Friedman ANOVA with Wilcoxon
matched-pairs test will be applied: 95% confidence inter-
vals based on Pearson-Clopper values will be computed
to estimate the reoperation rate in both groups. An un-
conditional test (Barnard’s test for superiority) for the ra-
tio of these two proportions will be used. A P-value less
than 5% will be considered statistically significant. All
analyses will be done by one of the authors (WH) using
STATISTICA 10 (Hill, T and Lewicki, P (2011). STATIS-
TICS: Methods and Applications. StatSoft, Tulsa, OK,
USA), StatXact 6.0 (Cytel Software Corporation (2003)
Cytel Software Corporation, Cambridge MA, USA),
NCSS 8 and PASS 11 Hintze, J (2012), NCSS 8, NCSS,
LLC, Kaysville, UT, USA. (www.ncss.com).
Monitoring
Data monitoring
Standard operating procedures for key processes in the
study have been developed. Prior to recruitment, the
field team will receive extensive training on the objec-
tives, methods and processes of the study, as well as on
the concept of ethical research. All case report form
(CRF) data for each participant will be controlled and
signed by a second investigator at this study site. Subse-
quently, the entered data are systematically checked
by medically trained personnel. Errors with obvious
corrections will be corrected by the medically trained
personnel and communicated to the site. The CRF will
be inspected by a monitor at regular intervals through-
out the study to verify the adherence to the protocol and
the completeness, consistency and accuracy of the data
being entered on them.
DSMB
A DSMB (Data Safety Monitoring Board) will ensure
the monitoring of adverse events (AEs)/severe adverse
events (SAEs) and adverse drug reactions (ADRs) during
the study.Waived SAEs
The decision to have waived SAEs is appropriate when
the safety and tolerability profile of the study drug dexa-
methasone has been well-characterized, allowing a clear
understanding of the difference between drug-related
and disease-related AEs. The SAEs listed below are due
to the underlying disease, and are therefore expected to
occur in this patient population. In this study, they will
be waived. This means that they will not require report-
ing to the sponsor drug safety database on an SAE form,
but that they will be reported as serious only on the AE
pages of the CRF. Therefore, they will be entered only
into the Sponsor’s clinical database. The waived SAEs
for this study are the following: 1) any type of cerebral/
brain infarction or stroke; 2) cerebral/brain hemorrhage
or hematoma; 3) delayed ischemic neurological deficit,
neurological deterioration, delirium, confusion, disorien-
tation, aphasia, paresis/paralysis (including hemiparesis,
limb weakness, specified limb paralysis); 4) cranial nerve
palsies; 5) complications related to the initial haematoma
evacuation procedure; 6) brain edema; 7) hydrocephalus;
8) intracranial hypertension; 9) meningitis, ventriculitis,
encephalitis; and 10) seizure.
Interim analysis
There will be no interim analysis performed.
Auditing
Quality control audits of the database will be made be-
fore study closure.
Informed consent
All eligible patients will be presented with a form for
written informed consent. The form will also be verbally
explained. A signature will be obtained from all those
who consent to participate respectively or from their
legal representative. The written informed consent form
will be in Chinese, English and German.
Ethical issues
The protocol received Salzburg Ethics Committee ap-
proval, and was approved by the BASG (Austrian health
products safety agency). The trial is conducted in com-
pliance with the European Union Clinical Trials Direct-
ive (2001/20/EC), the Public Health Code of Ethics, the
International Conference on Harmonization guidelines
for Good Clinical Practice (CPMP/ICH/135/95) and the
principles of the Declaration of Helsinki (1996).
Discussion of underlying literature
Despite 2,335 papers about cSDH identified in a recent
PubMed search, treatment has not changed much. The
main problem is the persistent recurrence. Glucocorti-
coids have a special capacity to block the inflammatory
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ally inhibit lymphokins and prostaglandins and stimulate
inflammatory inhibitors like lipocortin. Thus, the grow-
ing of neomembranes and neocapillaries is impaired
[3,19,20]. On the one hand cortisone reduces the expres-
sion of vascular epithelial growth factor (VEGF), which
inhibits abnormal angiogenesis. On the other hand it in-
duces the secretion of the inhibitor of plasminogen, so
that the cycle of re-bleeding and lysis is decelerated [3].
Several retrospective [21,27,30-36] and two prospective
[25,28] studies about the use of cortisone in cSDH have
been published. Two representative trials are discussed. In
the first of the retrospective studies [30] 122 patients were
enrolled and divided into two groups: Subjects with a good
neurological condition (Markwalder grading score (MGS) 0
to 2) were assigned to the dexamethasone protocol, whereas
patients with MGS 3 to 4 were assigned to a surgical proto-
col. Of the 122 patients, 101 were on dexamethasone, and
22 of them ultimately required a surgical drain (21.8%{). A
favorable outcome (MGS 0, 1, or 2) was obtained in 96%
and 93.9% of those treated with dexamethasone and surgical
drain, respectively. The overall mortality rate was 0.8% and
readmissions related to the hematoma reached 14.7%. The
study medication comprised administration of 4 mg dexa-
methasone every 8 hours for 3 days, tapering to 1 mg every
3 days. In total the medication lasted for 36 days.
The second study [21] was of 142 patients treated with
methylprednisolon and surgery, and 56 patient who only
received surgery. The cortisone therapy decreased the
risk of death threefold. Methylprednisolone was applied
in a dosage of 0.5 mg/kg/day postoperatively for 30 days
and was slowly tapered down subsequently.
The disadvantage of both cortisone protocols is their
long duration and necessity of tapering the drug dose.
There were medical complications in 27.8% of the dexa-
methasone group. Thus, the DRESH study has a drug
application for 6 days only. The principal purpose is the
proof of a practicable concomitant medication that has
low incidence of side effects and is efficient, however.
Sun [25] prospectively enrolled a cohort of 112 patients
and allocated them to four groups: burr-hole irrigation
alone, dexamethasone with surgery, dexamethasone with-
out surgery, and a small group treated only conservatively.
Dexamethasone as a single treatment was administered
four times daily (4 mg each) over 21 days, whereas in the
dexamethasone plus surgery group the cortisone applica-
tion started 48 hours preoperatively and was tapered over
the next two weeks. Cortisone as a single treatment was
equal to a combined treatment, because (re)operation was
4% in both groups. However, sole surgery resulted in a re-
operation rate of 15%. Due to the small series no signifi-
cant advantage of cortisone could be proven. There is a
sense that a combined treatment is able to reduce the ster-
oid dosage without affecting the recurrence rate.Park [28] performed a fibrinogen and D-dimer analysis
in cSDH and investigated 31 patients prospectively. All
patients underwent burr-hole surgery and only one pa-
tient (3.2%) needed to undergo repeat surgery. This very
low relapse rate is perhaps due to a concomitant dexa-
methasone medication for one week after the procedure.
The DRESH also uses the cortisone application post-
operatively. Compared to a preoperative regime the ad-
vantage of a postoperative study drug administration is
to additionally include patients who require urgent sur-
gery. In spite of different study designs and surgical
techniques the published data seem encouraging for a
benefit of a steroid co-medication, even over a short
period of time.
Methodology
The DRESH study has a straightforward design: on the
one hand an efficient concomitant treatment which
should be evaluated to the highest evidence possible,
and on the other hand the study dependent measures
are perfectly integrated into the clinical routine. In the
light of this aspect three points are worth mentioning: a
clear study design and statistics, waived SAEs and a
maximal time frame for randomization. Even patients
who undergo emergency surgery can be randomized
postoperatively. Most of the exclusion criteria are due to
the use of dexamethasone or anticoagulant drugs. There
is a simple primary endpoint defined without any surro-
gate parameter: reoperation. The reoperation rate should
be decreased by 50%, because only 82 patients out of
820 (assumed reoperation rate of 10%) are affected and
might benefit from the cortisone regime. In the case of a
reduction in reoperation less than 50% more than 95%
of the study population would take dexamethasone in
vain. The surgical procedure has been standardized in
order to achieve meaningful statistics.
The national authorities concerned have allowed waiv-
ing of particular SAEs, because dexamethasone has been
used for decades. Hence, there is a clear understanding
of the difference between drug-related and disease-
related AEs. Evaluation of secondary objectives will be
very lucrative because of the huge sample size. It will
offer a refined knowledge of risk factors, the role of co-
medication and radiologic findings. Nevertheless, the
DRESH study has to clear two hurdles: to be the first
RCT to prove significant efficacy for cortisone in the
treatment of cSDH in general, and to test a reasonable
medication dosage as a relapse prevention for surgical
patients in particular.
In the event of significant results a powerful adjuvant
therapy in preventing patients from reoperation is of-
fered. For multi-morbid patients with high risk for sur-
gery, a stand-alone therapy with dexamethasone is
conceivable.
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The anticipated start is at the beginning of February
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